Abstract | BACKGROUND: OBJECTIVES: The aim of this study is to: (1) identify clinical characteristics of patients who develop breakthrough FN, and (2) provide descriptive data on the incidence of breakthrough FN among lymphoma patients. METHODS: This is a single-centre, retrospective cohort study. Non-Hodgkin's lymphoma patients who received CHOP-based chemotherapy with pegfilgrastim between January 2007 and May 2009 were identified through the Singapore Lymphoma Registry. Patient demographics, past and present medical history, cancer treatment history and laboratory parameters were collected from electronic databases and medical records. In this study, patients did not receive oral antibiotic prophylaxis along with chemotherapy. RESULTS: A total of 132 patients were included in the final analysis. Median age of patients was 55 years. The incidence of breakthrough FN among patients in cycle 1 and across all cycles was 4.5% and 13.6%, respectively (n = 132). 3.3% (n = 60) of the patients receiving dose-dense chemotherapy had breakthrough FN, and this was 22.2% (n = 72) in patients receiving standard dose chemotherapy. Administration of chemotherapy every 21 days (adjusted OR = 12.1, p = 0.009) and patients with positive blood cultures (adjusted OR = 18.1, p = 0.001) were strongly associated with the occurrence of breakthrough FN. CONCLUSION:
|
Authors | Jia Hui Ng, Xiu Yun Ang, Sze Huey Tan, Miriam Tao, Soon Thye Lim, Alexandre Chan |
Journal | Acta haematologica
(Acta Haematol)
Vol. 125
Issue 3
Pg. 107-14
( 2011)
ISSN: 1421-9662 [Electronic] Switzerland |
PMID | 21109731
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 S. Karger AG, Basel. |
Chemical References |
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- pegfilgrastim
- Polyethylene Glycols
- Filgrastim
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cohort Studies
- Female
- Fever
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Humans
- Lymphoma, Non-Hodgkin
(complications, drug therapy)
- Male
- Middle Aged
- Neutropenia
(drug therapy, prevention & control)
- Polyethylene Glycols
- Premedication
(methods)
- Recombinant Proteins
- Retrospective Studies
- Risk Factors
|